New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...

Collegium Pharmaceutical’s pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of ...

"These posters include important scientific data for healthcare professionals to consider concerning the safety profile of buprenorphine buccal film and oxycodone," said Thomas Smith, MD, Chief ...

noticing your pain getting worse. If your pain gets worse after you take BELBUCA, do not take more of BELBUCA without first talking to your healthcare provider. Talk to your healthcare provider if the ...

RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic ...

Collegium Pharmaceutical is rated a Buy after a guidance cut and stock drop, with the market pricing in an overly pessimistic ...

A new medication for chronic pain has been approved in the United States, a buprenorphine buccal film product, trade name: Belbuca. It is indicated for the treatment of chronic pain severe enough to ...

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE ...